| Name | Title | Contact Details |
|---|
Based in Rockville, Maryland, OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease.
Ben Venue Labs is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioAgilytix is a leading bioanalytical contract research organization (CRO) that supports the development of novel therapeutic biologics and biosimilars. Located in Research Triangle Park, North Carolina, BioAgilytix specializes in large-molecule bioanalysis providing critical insight into the safety, efficacy, and mechanism of action of drug candidates throughout the clinical trial process. Specifically, BioAgilytix offers assay development, validation, and sample analysis services for immunoassays and cell-based assays under non-GLP, spirit-of-GLP, and GLP, as well as product release testing under GMP. BioAgilytix is an engaged and energetic partner committed to delivering exceptional value and veteran expertise through a collaborative process that consistently results in successful projects.
Praxis is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance.
The world leader in addiction treatment with over 20 years of experience and a patient-focused approach. We didn`t become the world leader in addiction treatment overnight. Our endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported. They`re often unaware of their treatment options, have limited access to treatment, or simply don`t seek it out because they`re afraid of being stigmatized. Since our inception, we have actively partnered with healthcare professionals, the public health community, policy makers, and payers to humanize people suffering from addiction and to treat addiction as a chronic, relapsing medical condition rather than a social disorder. We believe that people with addiction should be treated as patients, just like people with other chronic diseases. The past two decades have been marked by strong growth and an expansion into more than 40 countries. While treatment for opioid use disorder has seen much innovation, we at Indivior are building on our intimate understanding of the patient journey to further advance addiction treatment including opiate overdose, alcohol use disorders, and co-occurring conditions such as schizophrenia by bringing to market novel treatment solutions worldwide. We at Indivior are on an endeavor – one that is focused on individual patients around the world. Our name reflects this as the key words individual and endeavor harmoniously blend together. It represents and empathizes with the often difficult journey each individual patient takes to overcome the challenges of addiction – a chronic relapsing disease. The patient continues to drive our decisions. Our guiding principles foster a corporate culture of trust, innovation, and a pioneering spirit. We work with the urgency and zeal required to achieve our vision that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction.